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streptozotocin‑induced diabetic rats by reducing 
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In this study, we investigated the protective effects of angiotensin IV (Ang IV) on cognitive function in streptozotocin (STZ)‑induced 
diabetic rats. Male Wistar albino rats, were randomly divided into four groups; control (C), diabetes (Dia, 60 mg/kg, STZ, i.p.), Ang IV 
(5 µg/kg, s.c.) and Dia+Ang IV. The passive avoidance and Morris water maze (MWM) tests were used to evaluate learning and memory 
performance. Behavioral tests were carried out between 21 and 30 days after the initial Ang IV injection. Hippocampi were dissected 
and retained for biochemical and Western blot analysis. The Dia group exhibited the poorest behavioral results, while the Dia+Ang IV 
group performed highest on the MWM task. Superoxide dismutase, glutathione peroxidase, and malondialdehyde levels increased 
significantly in the Dia group compared to Dia+Ang IV. Brain‑derived neurotrophic factor (BDNF) and N‑methyl‑D‑aspartate levels were 
significantly elevated, while levels of GABAA significantly decreased, in the Dia+Ang IV group compared to the Dia group. These findings 
suggest that peripheral administration of Ang IV ameliorated spatial memory in diabetic rats by decreasing hippocampal oxidative 
stress and BDNF levels. 
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INTRODUCTION
Diabetes mellitus (DM), which has been rapidly in‑
creasing in prevalence worldwide, causes many com‑
plications in the body, particularly structural and 
functional disorders in peripheral and central nervous 
system (Charnogursky et al., 2014). Hyperglycemia is 
known to cause cognitive dysfunction in individuals 
with DM (Saedi et al., 2016). Although the underlying 
pathophysiology of cognitive dysfunction in diabetic 
patients has not been fully elucidated, cerebrovascu‑
lar and neurodegenerative alterations are thought to 
play a role in the cognitive impairments. It has been 
suggested that disturbances in receptor levels and neu‑
rotransmitter release may lead to apoptosis in neurons 
which might impair cognitive function in individuals 
with DM (Moheet et al., 2015; Sadeghi et al., 2016). 
DM is also defined as a chronic metabolic disorder as 
it is characterized by increased oxidative stress. It has 
been reported that oxidative stress contributes greatly 
to the development of diabetes‑related complications 
(Asmat et al., 2016).
Since the discovery of renin in 1898, many studies 
have investigated the renin angiotensin system (RAS) 
(Tigerstedt and Bergman, 1898). This complex system 
has important physiological functions in regulating 
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water and electrolyte balance, systemic vascular resis‑
tance, blood pressure and cardiovascular homeostasis. 
However, chronic activation of the classical RAS may 
cause oxidative stress, endothelial dysfunction and 
inflammation, which leads to many pathological con‑
ditions ranging from hypertension and kidney disease 
to heart failure (Mentz et al., 2013). Furthermore, re‑
cent data suggests that inhibition of this system may be 
useful in reducing cognitive impairment, which is ob‑
served during aging, Alzheimer’s disease, Parkinson’s 
disease and post‑stroke cognitive impairment (Fouda et 
al., 2016; Hamel et al., 2016).
Angiotensin IV (Ang IV), which is formed from 
angiotensin II (Ang II) by aminopeptidases, is an en‑
dogenous peptide and a primary molecule involved in 
the RAS. Ang IV and its analogs do not activate any 
of type 1 or type 2 Ang II receptors, unlike Ang II, 
because the effects of Ang IV are mediated by a dif‑
ferent receptor called angiotensin type 4 receptor 
(AT4R) (Royea et al., 2017). AT4R activation is thought 
to enhance cognition, cell signaling and synaptic con‑
duction, and has antioxidant and anti‑inflammatory 
properties (Albiston et al., 2003). The AT4R signaling 
mechanism in the hippocampus of rodents has been 
shown to activate acetylcholine and glutamate release 
and induce long‑term potentiation (LTP) (Jackson et 
al., 2018). In addition, inadequate AT4R signaling may 
lead to impaired neurotransmitter release and synap‑
tic dysfunction, which may lead to impaired cognitive 
function.
Previous studies on the positive effects of Ang IV 
on learning and memory have led to the question of 
whether it might play a curative role in cognitive dis‑
orders that develop in DM. Therefore, in this study, we 
aimed to investigate the effect of Ang IV on hippocam‑
pal oxidative stress and diabetes‑induced impairments 
in cognitive function in streptozotocin (STZ)‑induced 
diabetic rats. The possible mechanisms underlying 
its effect on cognitive functions were investigated by 
measuring levels of N‑methyl‑D‑aspartate (NMDA) and 
gamma‑aminobutyric acid A (GABAA) receptors, as well 
as brain‑derived neurotrophic factor (BDNF), as molec‑
ular markers of hippocampus‑dependent mechanisms 
of learning and memory.
METHODS
Ethics and animals
Thirty‑two male Wistar albino rats, weighing be‑
tween 350–400 g were used. The animals were obtained 
from the Bezmialem Vakif University Experimental 
Animal Centre and housed under standard laboratory 
conditions (12 h light/dark cycles, 22°C and 60% hu‑
midity), with ad libitum food and water, and received 
humane care according to the criteria outlined in the 
“Guide for the Care and Use of Laboratory Animals” 
prepared by the National Academy of Science and 
published by the National Institutes of Health. Ethical 
regulations were followed in accordance with The Na‑
tional and Institutional guidelines for the protection 
of animal welfare during all experiments. All animal 
procedures were approved by the Laboratory Animals 
Ethical Committee of Bezmialem Vakif University 
(2018/150).
Experimental groups and chemicals
At the beginning of the experiment, animals were 
divided randomly into four groups; control (C, n=8), 
angiotensin IV (Ang IV, n=8), streptozotocin (STZ)‑in‑
duced diabetes mellitus (Dia, n=8) and STZ‑induced di‑
abetes mellitus and angiotensin IV (Dia+Ang IV, n=8). 
Diabetes was induced by an intraperitoneal (i.p.) injec‑
tion of 60 mg/kg STZ (Sigma‑Aldrich, Munich, Germa‑
ny) dissolved in citrate buffer (pH: 4.5). An equal vol‑
ume (1 ml) of citrate buffer was injected into the control 
group. Before STZ/citrate buffer injection, initial blood 
glucose levels were measured from blood obtained from 
the tip of the rat tails with a glucometer (AccuCheck 
Nano, Roche, Switzerland). Three days after STZ injec‑
tion, blood glucose levels were re‑measured, and rats 
with blood glucose values over than 200 mg/dl were 
accepted as diabetic, which has also been accepted 
by other research studies (Katsumata and Katsumata, 
1992; Patel et al., 2006). Ang IV (Sigma‑Aldrich, Munich, 
Germany) was dissolved in 1 ml saline (5 µg/kg) (Gard 
et al., 2012; Fidalgo et al., 2017) and administered sub‑
cutaneously to the rats in the Ang IV and Dia+Ang IV 
groups for 21 days from the day the rats were accepted 
as diabetic (Day 1 of the experiment). Equal volumes of 
saline were injected subcutaneously into the rats in the 
C and the Dia groups. 
Learning and memory was evaluated between the 
Day 21 and Day 30. All animals were weighed and their 
blood glucose levels were measured at Day ‑3, Day 1, 
Day 14, Day 21and Day 30 of the experiment (Fig. 1). 
Behavioral tests
Passive avoidance task
The passive avoidance task was performed on Day 
21 of the experiment. A shuttle box consisted of two 
parts, a light compartment and a dark compartment 
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separated by a guillotine door (MAY‑APAV‑214 ELS, 
MAY‑PA1014, Commat Ltd., Cankaya, Ankara). The test 
consisted of two stages: an acquisition and retention 
session. During the acquisition period (Day 21), all ex‑
perimental animals were first habituated to the equip‑
ment. The animal was placed in the light chamber and 
20 s later, the guillotine door was opened. After the 
rat entered into the dark compartment, a foot shock 
(1 mA) was delivered for 2 s. At the end of the acqui‑
sition trial the rat was removed from the apparatus 
and placed in its home cage. The retention tests were 
performed 24 hours after training to evaluate memory 
function (Day 22). For the retention test, each animal 
was placed in the light compartment, and the session 
ended when the animal entered the dark compartment 
or if it remained in the light compartment for 300 s. In 
these sessions, no electric shock was given to the ani‑
mals. Time spent to enter the dark compartment was 
measured.
Morris water maze
The Morris water maze (MWM) test was used to eval‑
uate hippocampal spatial learning and memory. A cir‑
cle pool (150 cm in diameter and 51 cm high) was filled 
with opaque‑colored (non‑toxic dye) water (23±1°C) 
to a depth of 45 cm and divided into four quadrants 
(north, south, east and west). A computerized video 
tracking system (Ethovision XT Noldus Information 
Technology, The Netherlands) was used to track the an‑
imal in the pool and record the data. A movable escape 
platform (11 cm x 11 cm) was placed in the west quad‑
rant (target quadrant) of the pool, hidden 2 cm below 
the water surface. Geometric visual cues were located 
on the walls of experimental room. The test included 
an acquisition period (Day 24‑Day 29) and probe trial 
(Day 30). During the acquisition period, each rat per‑
formed 4 trials per day for 5 days. Rats were randomly 
introduced into the pool from different quadrants, fac‑
ing the wall, and allowed 60 s to locate the escape plat‑
form. If the rats did not find the platform within 60 s in 
the first trial, they were gently guided to the platform 
and allowed to remain for 30 s. The rat was then re‑
turned to its home‑cage for a 5 min inter‑trial interval. 
Swim latency, swim velocity and swim distance to find 
the escape platform during training were automatical‑
ly recorded using the video tracking system. On the 
sixth day of the test, during the probe trial (Day 30), 
rats were assessed in the pool and allowed to swim for 
60 s with no platform. At the end of the probe trial, the 
percentage of time spent in the platform quadrant was 
recorded for each animal.
Biochemical analysis
Upon the completion of behavioral testing (Day 30), 
rats were anesthetized, decapitated, and their brains 
were removed and the hippocampi were dissected for 
molecular and biochemical analysis. The hippocam‑
pus was frozen on ice and stored at 80°C. The tissue 
samples were homogenized with PBS (phosphate buff‑
ered saline, pH: 7.4) using a steel bead homogenizer 
(Retsch MM400, Haan, Germany) in 2 ml microtubes. 
The homogenates were then taken into microtubes 
and centrifuged at 15,000 x g for 20 min at 4°C. First, 
the total protein content of supernatants was deter‑
mined by the Bradford method (Kruger, 2009). The 
tissue homogenates’ malondialdehyde (MDA) (Sino‑
GeneClon Biotech, HangZhou, China) glutathione per‑
oxidase (GSH‑Px) (SinoGeneClon Biotech, HangZhou, 
China), superoxide dismutase (SOD) (Y&L Biotech Co, 
Shanghai, China), and BDNF (SinoGeneClon Biotech, 
HangZhou, China) levels were determined by ELISA 
using corresponding kits according to manufacturers’ 
instructions.
Fig. 1. Experimental timeline.
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Western blotting assay
The hippocampi were dissected and homogenized 
in lysis buffer containing protease inhibitor cocktails 
(MP FastPrep‑24, USA). The homogenates were cen‑
trifuged at 14,000 x rpm (Beckman Coulter, Krefeld, 
Germany) for 10 min at 4°C, and the final supernatant 
was used as the cytosolic fraction. Total protein con‑
centrations of supernatants were measured using the 
Bradford method at a 595 nm wavelength (Thermo Sci‑
entific Multiskan FC, 2011‑06, USA). The supernatants 
were used for sodium dodecylsulphate‑polyacrylamide 
gel electrophoresis (SDS‑PAGE). After the proteins were 
transferred onto a polyvinylidene difluoride (PVDF) 
membrane, the membranes were incubated in blocking 
solution (5% skimmed milk) and immersed into primary 
antibody and horseradish peroxidase (HRP)‑ conjugat‑
ed secondary antibody solutions (Cell Signaling Tech‑
nology). Protein bands for anti‑GABAA receptor alpha 
(Novusbio, Centennial, USA), ACE2 (GeneTex, Irvine, 
California, USA) and NMDAR2A antibody (Novusbio, 
Centennial, Colorado, USA) were visualized with che‑
miluminescence (ECL) Western blot substrate (Pierce, 
Thermo Scientific, USA). Glyceraldehyde‑3‑phosphate 
dehydrogenase (GAPDH) (Cell signal, USA) was used as 
a housekeeping reference antibody.
Statistical analysis
Group means ± standard error of mean (SEM) were 
calculated for all values. The Shapiro–Wilk test was 
used to test the normality of the data. The biochemical 
and western blotting assay results for tissue samples 
in different groups were analyzed by one‑way ANOVA, 
and the behavioral tests were compared using two‑way 
ANOVA, one‑way ANOVA and Kruskal Wallis tests. 
Post‑hoc comparisons between the groups were per‑
formed with Bonferroni and Dunn tests using GraphPad 
Prism software (GraphPad Prism Version 6 Software 
Program San Diego, CA). A value of p<0.05 was consid‑
ered statistically significant.
RESULTS
Changes in body weights  
and blood glucose levels
On the Day 14 of the experiment, significant de‑
creases were observed for body weight in the Dia and 
the Dia+Ang IV groups compared to control (p<0.01 and 
p<0.001, respectively), which were maintained at Day 
21 and Day 30 (p’s<0.001) (Fig. 2). There was no signifi‑
cant difference in the initial blood glucose levels among 
groups (Day 3). Both diabetic groups (Dia and Dia+Ang 
IV) showed significantly (p<0.001) higher blood glucose 
levels than the control group on the Days 1, 14, 21 and 
30 (Table I).
Behavioral tests
The mean swim latency and the mean swim distance 
for all groups decreased from the 1st training day to the 
5th training day (p<0.001) However, there were no sig‑
nificant differences between groups for swim latency 
Table I. Changes in animal blood glucose levels (n=8) during the experiment.
Groups Day ‑3 (mg/dl) Day 1 (mg/dl) Day 14 (mg/dl) Day 21 (mg/dl) Day 30 (mg/dl)
C 110.875±1.6 105.125±2.5 107.375±2.7 104.250±2.8 104.250±2.8
Ang IV 108.125±2.5 115.750±3.7 105.750±1.8 104.500±2.1 104.500±2.1
Dia 101.125±2.1 506.875±21.8*** 520.125±22*** 520.875±23.1*** 549.375±22***
Dia+Ang IV 108.125±2.8 413.875±18.3*** 525.125±26.1*** 495.875±26.6*** 513.250±32***
Data were presented as mean ± SEM. ***p<0.001, represents statistical significance compared to control group.
Fig.  2. Changes in body weight of animals (n=8) during the experiment. 
Data is presented as mean ± SEM. **p<0.01, and ***p<0.001, represent 
statistical significance determined using one‑way ANOVA followed by 
Bonferroni post‑hoc test.
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or swim distance on the first three training days. On 
Day 4 and 5, both swim latency and swim distance of 
the Dia group were significantly higher than in the 
control group (p’s<0.001), which indicates an impair‑
ment in learning performance (Fig. 3A and 3B). On the 
other hand, in the Dia+Ang IV group, both swim laten‑
cy and swim distance were significantly lower than the 
Dia group on both Day 4 and 5 (p’s<0.001), indicating 
relatively better learning (Fig. 3A and 3B). There was 
a significant difference between the Dia+Ang IV group 
and the control group (p<0.001) for swim latency on 
Day 4, however, this difference was no longer detect‑
able on Day 5 (Fig. 3A).
Furthermore, swim distance was significantly lower 
in the Ang IV group compared to the control group on 
the 4th day of MWM training (p<0.01). In addition, com‑
pared to the Dia group, swim distance was significantly 
lower in the Ang IV group on Day 4 and 5 (p’s<0.001). 
There were no significant differences for swimming ve‑
locity between groups for all 5 training days (Fig. 3C).
For the MWM probe trial, the Dia group spent less 
time in the platform area compared to the control 
group (p<0.05) (Fig. 4A). Time spent in the platform 
area was significantly higher in the Dia+Ang IV group 
compared to the Dia group, demonstrating enhanced 
learning performance (p<0.05) (Fig. 4A). 
In the retention trial of the passive avoidance task, 
the Dia group performed worse than the control group 
(p<0.05) (Fig. 4B). The Dia+Ang IV group exhibited 
a slightly better performance on passive avoidance 
compared to the Dia group, however, it did not reach 
the accepted significance level (Fig. 4B).
Biochemical results
The BDNF levels of hippocampus in the Dia group 
were significantly lower than in the control group 
(p<0.01). In the Dia+Ang IV (p<0.05) group, the levels 
of BDNF were significantly higher than the Dia group 
(Fig. 5A). The levels of SOD (Fig. 5B), GPx (Fig. 5C) and 
MDA (Fig. 5D) were significantly elevated in the Dia 
group compared to the C group (p<0.01). In addition, 
the levels of SOD, GPx and MDA in the Dia+Ang IV group 
were significantly lower (p<0.05, p<0.05, p<0.01, respec‑
tively) compared to the Dia group.
Western blotting assay
The highest levels of NMDA receptor expression 
were detected in the Ang IV group, and this elevation 
was statistically significant compared to the control 
group (p<0.001) (Fig. 6A). NMDA receptor expression 
Fig.  3. Behavioral tests for all groups (n=8). Mean swim latency (A), 
mean swim distance (B) and velocity (C) analyzed with two‑way ANOVA 
followed by Bonferroni post‑hoc test for the first 5 days of Morris Water 
Maze (MWM) training. Data is presented as mean ± SEM. **p<0.01, 
and ***p<0.001, represent statistical significance compared to the C 
group; +++p<0.001, represents statistical significance compared to the 
Dia group.
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in the Dia and the Dia+Ang IV groups was significantly 
lower than in the control group (p<0.001); however, it 
was significantly higher in Dia+Ang IV group compared 
to the Dia group (p <0.05) (Fig. 6A). 
The highest levels of protein expression for GABAA 
receptor were observed in the Dia group (p< 0.01) 
(Fig. 6B). GABAA receptor expression levels for the 
Dia+Ang IV group were significantly lower compared to 
the Dia group (p<0.05) (Fig. 6B). 
Lastly, the highest ACE2 levels were found in 
the Ang IV group (Fig. 6C). The expression level of 
ACE2 was significantly lower in both the Dia and the 
Dia+Ang IV groups compared to the control group 
(p<0.05). Surprisingly, ACE2 expression levels in the 
Dia group were significantly lower than the Dia+Ang 
IV group (Fig. 6C).
DISCUSSION
Injection of STZ, which induces one of the most 
common experimental diabetes model in rats, results 
in a number of diabetes‑specific symptoms such as de‑
creased body weight, hyperglycemia and neuroendo‑
crine disorders (Crawford, 2017). Blood glucose levels 
were found to be significantly elevated in both the Dia 
and the Dia+Ang IV groups and remained within nor‑
mal limits in both the control and the Ang IV groups 
throughout our study. The body weights of the dia‑
betic rats decreased significantly throughout the ex‑
periment, as shown in other studies (Pournaghi et al., 
2012; Wang‑Fischer and Garyantes, 2018). The body 
weights for both the control and the Ang IV groups in‑
creased slightly during the experiment. These results 
indicated that the dose of Ang IV used had no effect 
on blood glucose level and body weight in the STZ‑in‑
duced diabetes model.
Type 1 (T1DM) and type 2 diabetes mellitus (T2DM) 
have been associated with reduced performance in 
multiple domains of cognitive function. Cognitive 
deficits can occur at the very earliest stages of dia‑
betes and are further exacerbated by metabolic syn‑
drome due to hyperglycemia (Low et al., 1997). The 
duration of diabetes and glycemic control may have 
an impact on the type and severity of cognitive im‑
pairment (Zilliox et al., 2016). Indeed, in a previous 
study cognitive impairment was even identified sev‑
en days after STZ administration to rats (Liu et al., 
2016). In our study, both in the passive avoidance and 
MWM tasks, it was demonstrated that STZ injection 
disrupted both fear‑conditioned memory and spatial 
learning and memory. 
Several studies showed that intracerebroven‑
tricular (i.c.v.) injection of Ang IV or its analogues 
enhanced performance of rats in the MWM test (De 
Bundel et al., 2009; Lee et al., 2004; Wright and Hard‑
ing, 2009; Wright et al., 1999). In addition, Wright and 
Harding (2009) suggested that Ang IV increased the 
escape latency in the passive avoidance task. There 
are very few studies on the peripheral administration 
of Ang IV. Although Ang IV is thought to have a low 
blood brain barrier affinity (Ho et al., 2018), due to its 
low weight compared to other RAS components and 
impaired blood brain barrier permeability in STZ‑in‑
duced diabetes (Huber et al., 2006), the behavioral 
test finding suggests that a learning‑memory mech‑
Fig.  4. Behavioral tests for all groups (n=8). Percentage time spent 
in the platform quadrant (A) on the probe trial of MWM analyzed by 
one‑way ANOVA followed by Bonferroni post‑hoc test. The time spent 
to enter the dark compartment in Passive Avoidance (B) analyzed by 
Kruskal‑Wallis followed by Dunn’s post‑hoc test. Data is presented as 
mean ± SEM. *p<0.05, represents statistical significance compared to 
the C group; +p<0.05, represents statistical significance compared to 
the Dia group.
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anism is activated by reaching the hippocampus. In 
support, several studies, using different behavioral 
tests, demonstrated healing effects of subcutaneously 
administered Ang IV on memory (Fidalgo et al., 2017; 
Gard et al., 2012; Golding et al., 2010). In accordance 
with these studies, we showed that subcutaneous Ang 
IV injection ameliorated cognitive function. However, 
the ameliorative effect of Ang IV on spatial memory 
was more drastic than its effect on fear conditioning. 
The poor performance of rats in the passive avoidance 
task may be marked by increasing the dose of Ang IV. 
Effects of diabetes on the brain can include a re‑
ductions in antioxidant defense and a simultaneous 
increase in free radicals (Manschot et al., 2006). It is 
also known that hyperglycemia reduces antioxidant 
levels and concomitantly increases the production of 
free radicals (Muriach et al., 2014). The brain is consid‑
ered to be particularly vulnerable to oxidative damage 
due to its high oxygen consumption rate, high lipid 
content and relatively smaller amounts of antioxidant 
enzymes compared to other tissues. The findings of 
previous studies on the effects of STZ‑induced DM on 
the activity of antioxidant enzymes such as SOD and 
GPx in tissues are inconsistent. It has been suggested 
that SOD and GPx levels in DM rat brain increased in 
the early stages (8th week) of STZ injection, but their 
levels decreased due to severity of dyslipidemia in 
brain tissue in subsequent stages after DM formation 
(Yang et al., 2013). In addition, it was also reported 
that oxidative stress markers in brain tissue were in‑
creased by STZ injection (Bathina et al., 2017). Simi‑
larly, in our study, it was determined that STZ‑induced 
diabetes caused a significant increase in the levels of 
MDA, which are indicative of lipid peroxidation, and 
endogenous antioxidants SOD and GPx in the rat hip‑
pocampal tissue. 
Oxidative stress occurs in pathological conditions 
such as DM, when there is an imbalance between free 
radical activity and antioxidant activity (Birben et al., 
2012). Therefore, the reason for the lack of the oxi‑
dant markers and antioxidant markers in the Ang IV 
group may be related to the absence of oxidative dam‑
Fig. 5. The levels of hippocampal BDNF (A), SOD (B), GPx (C) and MDA (D) for each study group (n=8). BDNF; Brain derived neurotrophic factor, GPx; 
Glutathione peroxidase, SOD; Superoxide dismutase, MDA; Malondialdehyde. Data was analyzed using one‑way ANOVA followed by post‑hoc Bonferroni 
test and presented as mean ± SEM. **p<0.01, represents statistical significance compared to the C group; +p<0.05, and ++p<0.01, represent statistical 
significance compared to the Dia group. 
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Fig. 6. Western blotting assay results from hippocampi for each group (n=8). (A) NMDA; N‑methyl‑d‑aspartate, (B) GABAA; Gamma‑aminobutyric acid‑A, (C) 
ACE2; Angiotensin converting enzyme 2. Data was analyzed using one‑way ANOVA followed by post‑hoc Bonferroni test and presented as mean ± SEM. 
***p<0.001, represents statistical significance compared to the C group; +p<0.05, represents statistical significance compared to the Dia group.
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age (Muriach et al., 2014). Royea et al. (2020) indicat‑
ed that Ang IV reduced hippocampal oxidative stress. 
In support of this finding, the levels of MDA, SOD and 
GPx were significantly lower in the Dia+Ang IV group 
compared to the Dia group in our study. This suggests 
that Ang IV may act as an exogenous antioxidant to 
protect diabetic brain against oxidative damage‑in‑
duced neuropathology. 
While BDNF levels decreased in the Dia group, they 
increased in the Dia+Ang IV group. It is thought that 
low BDNF concentrations may contribute to cognitive 
impairment in diabetes (Zhong et al., 2019). Bathina 
et al. (2017) suggested that brain BDNF production 
is suppressed in STZ‑induced diabetic rats resulting 
in cognitive dysfunction and impaired learning and 
memory in DM. Furthermore, it was also suggested 
that the increment of BDNF in the hippocampus cor‑
relates with increasing antioxidant levels and, accord‑
ingly, there is an improvement in cognitive function 
(Jain et al., 2013). 
BDNF also promotes upregulation of NMDA recep‑
tors in the hippocampus (Caldeira et al., 2007). It is 
widely accepted that impaired synaptic plasticity or 
reduced activation of NMDA receptors will eventually 
result in spatial memory and learning disorders. In 
contrast, high GABA and GABAA receptor concentra‑
tions have been suggested to be associated with im‑
paired spatial memory and learning (Kumar Datusalia 
and Sunder Sharma, 2016; Van Bussel et al., 2016). It 
has been shown that hyperglycemia is closely related 
to reduction of NMDA receptor levels (Xu et al., 2006). 
As in our study, previous studies with STZ‑induced di‑
abetic rats showed a significant reduction in NMDA 
receptor subtypes (Bean et al., 2006; Kamal et al., 
2000). On the other hand, Ang IV treatment increased 
NMDA receptor levels and decreased GABAA receptor 
levels after STZ‑induced DM. Ang IV may have in‑
creased BDNF levels and altered the NMDA and GABAA 
receptor levels due to its antioxidant effect.
Ang (1‑7), another RAS component that is suggest‑
ed to play a role in cognitive function, is formed by 
ACE2 from Ang II. It is an endogenous peptide that 
acts primarily by binding to a G‑protein‑coupled re‑
ceptor called the MAS receptor (MasR) (Jiang et al., 
2014). Chen et al. (2017) found that brain ACE2 levels 
significantly decreased in diabetic rats, as observed in 
our Dia group. Surprisingly, in the present study, ACE2 
levels significantly increased in the Ang IV group 
whereas they decreased in the Dia+Ang IV group. It 
has been shown that the conversion of Ang (1‑7) by 
ACE2 may cause an increase in BDNF expression via 
the MasR (Kamel et al., 2018). In addition, another 
study suggested that ACE2 deficiency impaired cogni‑
tive function, which was associated with increased ox‑
idative stress and consequently decreased BDNF levels 
(Wang et al., 2016). However, according to our results, 
the lowest ACE2 levels, in the Dia+Ang IV group, may 
be independent of BDNF level. This could be due to 
Ang (1‑7) formation increasing with Ang IV adminis‑
tration, which may result in a healing effect on cogni‑
tive function. According to these results, it was con‑
cluded that Ang IV might contribute to the ACE2/Ang 
(1‑7)/MasR axis, however the findings relating to this 
pathway are inadequate in this study, and further in‑
vestigation is required.
CONCLUSION
In conclusion, as suggested by other studies, cog‑
nitive dysfunction due to hyperglycemia causes oxi‑
dative damage and our study suggests that systemic 
administration of Ang IV can significantly improve 
learning and memory performance even at the cellu‑
lar level, as demonstrated by increased NMDA recep‑
tor expression and BDNF levels and decreased GABAA 
receptor expression in hippocampus of rats. Addi‑
tionally, these alterations may be related to a par‑
tially curative effect of Ang IV on oxidative damage 
caused by diabetes. These findings also highlight the 
therapeutic potential of the peripheral administra‑
tion of Ang IV. 
LIMITATIONS
This study had a technical limitation. Due to tech‑
nical problems with equipment we could not measure 
blood pressure, which we had planned to perform with 
the non‑invasive tail‑cuff method.
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